The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Laser Surgery, Vienna, Juchgasse 25, 1030, Wien, Austria.
Graefes Arch Clin Exp Ophthalmol. 2013 Apr;251(4):1081-9. doi: 10.1007/s00417-012-2139-9. Epub 2012 Aug 29.
To evaluate the effect of half-fluence rate indocyanine green angiography (ICGA)-guided verteporfin photodynamic therapy (PDT) on macular sensitivity (MS) in eyes with acute symptomatic central serous chorioretinopathy (CSC).
Single-center consecutive case series by retrospective chart review. Sixteen eyes of 16 patients with acute CSC of 3 months duration or less, treated with half-fluence (25 mJ/cm(2)) ICGA-guided verteporfin PDT were reviewed. At baseline and after 1, 3, and 6 months, all patients underwent MS testing of the central 20 °, MS testing of the retinal area covered by the PDT laser spot (MSLS), and evaluation of fixation stability (FS) for the central two degrees with the MP-1 microperimeter (Nidek, Vigonza, Italy).
Macular sensitivity improved from 16.4 ± 3.0 dB at baseline (n = 16) to 18.2 ± 2.4 dB (p < 0.001) at 1 month (n = 16). At the 3-month (n = 13) and 6-month (n = 12) follow-up, MS stabilized at 19.5 ± 0.9 dB (p = 0.21) and 19.0 ± 1.3 dB (p = 0.74), without changes when compared to respective precedent follow-up. Mean MSLS improved from 12.9 ± 5.4 dB at baseline to 16.4 ± 4.9 dB (p < 0.001) after 1 month. At the 3- and 6-month follow-up, MSLS was 19.1 ± 1.2 dB (p= 0.1) and 18.9 ± 1.9 dB (p = 0.8) respectively. Mean FS at the central 2 ° was 78.8 ± 30.4 % before treatment and 81.8 ± 29.5 % (p = 0.7), 81.9 ± 27.5 % (p = 0.7) and 83.6 ± 17.1 % (p = 0.5) respectively 1, 3 and 6 months after treatment.
Half-fluence (25 mJ/cm(2)) PDT significantly increased mean MS of central 20 ° and mean MSLS, in eyes with acute symptomatic CSC. Fixation stability was stable at baseline and throughout 6 months of follow-up.
评估半剂量荧光素眼底血管造影（ICGA）引导下维替泊芬光动力疗法（PDT）对急性症状性中心性浆液性脉络膜视网膜病变（CSC）患者黄斑敏感性（MS）的影响。
通过回顾性图表审查进行单中心连续病例系列研究。纳入了 16 例 16 只眼，这些眼患有病程 3 个月或更短的急性 CSC，接受了半剂量（25mJ/cm2）ICGA 引导下维替泊芬 PDT 治疗。在基线时以及治疗后 1、3 和 6 个月时，所有患者接受中央 20°的 MS 测试、PDT 激光斑覆盖的视网膜区域的 MS 测试（MSLS）以及中央两度的固定稳定性（FS）评估（Nidek，Vigonza，意大利）使用 MP-1 微视野计。
黄斑敏感性从基线时的 16.4 ± 3.0dB（n = 16）提高至治疗后 1 个月时的 18.2 ± 2.4dB（p < 0.001）（n = 16）。在 3 个月（n = 13）和 6 个月（n = 12）随访时，MS 稳定在 19.5 ± 0.9dB（p = 0.21）和 19.0 ± 1.3dB（p = 0.74），与各自的前次随访相比没有变化。MSLS 均值从基线时的 12.9 ± 5.4dB 提高至治疗后 1 个月时的 16.4 ± 4.9dB（p < 0.001）。在 3 个月和 6 个月随访时，MSLS 分别为 19.1 ± 1.2dB（p=0.1）和 18.9 ± 1.9dB（p = 0.8）。中央 2°的平均 FS 在治疗前为 78.8 ± 30.4%，治疗后为 81.8 ± 29.5%（p = 0.7）、81.9 ± 27.5%（p = 0.7）和 83.6 ± 17.1%（p = 0.5）。
半剂量（25mJ/cm2）PDT 可显著提高急性症状性 CSC 患者中央 20°和中央 MSLS 的平均 MS。在整个 6 个月的随访过程中，固定稳定性在基线时保持稳定。
